AMAL

Amalgamated Financial Corp. Reports Fourth Quarter 2023 Financial Results: $170.8 Million Deposit Growth Excluding Brokered CDs; Net Interest Margin Rises to 3.44%

Retrieved on: 
Thursday, January 25, 2024
Income tax, Amalgamation, AMAL, PACE, CECL, Total, Amalgamated Bank, Share repurchase, Earnings call, Sale, GAAP, Common equity, PACS, Capital, Eastern Time Zone, Bank

Net interest income was $67.3 million for the fourth quarter of 2023, compared to $63.7 million for the third quarter of 2023.

Key Points: 
  • Net interest income was $67.3 million for the fourth quarter of 2023, compared to $63.7 million for the third quarter of 2023.
  • Net interest margin was 3.44% for the fourth quarter of 2023, an increase of 15 basis points from 3.29% in the third quarter of 2023.
  • Core non-interest income1 was $8.5 million for the fourth quarter of 2023, compared to $7.8 million in the third quarter of 2023.
  • Core non-interest expense1 for the fourth quarter of 2023 was $37.7 million, an increase of $0.7 million from the third quarter of 2023.

Amalgamated Financial Corp. Declares Regular Quarterly Dividend

Retrieved on: 
Tuesday, January 23, 2024
AMAL

NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced that its Board of Directors has declared a regular dividend to common stockholders of $0.10 per share, payable by the Company on February 23, 2024, to stockholders of record on February 6, 2024.

Key Points: 
  • NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced that its Board of Directors has declared a regular dividend to common stockholders of $0.10 per share, payable by the Company on February 23, 2024, to stockholders of record on February 6, 2024.
  • The amount and timing of any future dividend payments to stockholders will be subject to the discretion of the Board of Directors.

Amalgamated Financial Corp. Announces Fourth Quarter and Full Year 2023 Earnings Conference Call

Retrieved on: 
Thursday, January 11, 2024
AMAL

NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced that its fourth quarter and full year 2023 financial results will be released before market open on Thursday, January 25, 2024.

Key Points: 
  • NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced that its fourth quarter and full year 2023 financial results will be released before market open on Thursday, January 25, 2024.
  • The Company will host a conference call at 11:00 a.m. Eastern Time on the same day to discuss the financial results.
  • Investors and analysts interested in participating in the call are invited to dial 1-877-407-9716 (international callers please dial 1-201-493-6779) approximately 10 minutes prior to the start of the call.
  • A live audio webcast of the conference call will be available on the website at https://ir.amalgamatedbank.com/ .

Medical Technology Innovator Thornhill Medical’s MOVES® SLC™ is acquired for United States Marine Corp En Route Care Modernization and added to Authorized Medical Allowance List (AMAL) 647

Retrieved on: 
Wednesday, December 6, 2023
Trauma, Suction, Marine Corps Expeditionary Medal, Medicine, Acquisition, United States Navy, Role, Oxygen, AMAL, Transport, Patient, USMC, Nursing care plan, Vital signs, VADM, Military medicine, Hospital

TORONTO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Medical technology innovator Thornhill Medical is pleased to announce that the United States Marine Corps (USMC) has acquired its integrated life support technology, MOVES® SLC™.

Key Points: 
  • TORONTO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Medical technology innovator Thornhill Medical is pleased to announce that the United States Marine Corps (USMC) has acquired its integrated life support technology, MOVES® SLC™.
  • The acquisition supports USMC En Route Care modernization goals using state-of-the-art, lightweight, critical care equipment to successfully transport patients from Role 2 to Role 3 care.
  • MOVES® SLC™ has also been formally added to the U.S. Marine Corps’ Authorized Medical Allowance List (AMAL) 647 for En Route Care.
  • The game-changing MOVES® SLC™ system addresses the need for medical technology that is smaller, lighter, more durable, flexible and easy to maintain, and less reliant on supply chain.

Amalgamated Financial Corp. Appoints Julieta Ross and Scott Stoll to its Board of Directors

Retrieved on: 
Thursday, November 16, 2023
First Franklin Financial Corp., M&T Bank, Acquisition, Research, Ernst & Young, Audit committee, Citigroup, Risk management, Business, Executive Committee, Farmer, Chairperson, Insurance, Faculty, Strategic planning, Leadership Council, EY, The Co Founder, AMAL, Banco Santander, AAA Western Valley District, Farmers Insurance Group, Bowling Green State University, Banco, Management, Amalgamation, Central New York

NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced it has appointed Julieta Ross and Scott Stoll as its newest members to the Company’s Board of Directors, effective immediately.

Key Points: 
  • NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced it has appointed Julieta Ross and Scott Stoll as its newest members to the Company’s Board of Directors, effective immediately.
  • Dr. Ross has an extensive background in the broader financial services risk management landscape, with over 20 years of global banking technology leadership and experience.
  • Lynne Fox, Board Chair, commented, “Julieta and Scott bring impressive track records in the broader financial services and banking sectors to Amalgamated’s board of directors, making them the ideal candidates for this role.
  • Prior to this, Mr. Stoll’s role focused on commercial banking risk management and asset liability management from 1994 to 2000.

Amalgamated Financial Corp. Reports Third Quarter 2023 Financial Results; Stable Net Interest Margin at 3.29%, Deposit growth excluding Brokered CDs of $172.8 million

Retrieved on: 
Thursday, October 26, 2023
Earnings call, Sale, Eastern Time Zone, Amalgamation, PACE, Share repurchase, GAAP, Trust, First Franklin Financial Corp., Risk-weighted asset, Amalgamated Bank, Common equity, CECL, PACS, Total, AMAL, Security (finance), Uranium mining, Bank, Insurance, Pharmaceutical industry, Real estate, Video game

Net interest income was $63.7 million and net interest margin was 3.29%, with each better than the guidance range provided in the second quarter.

Key Points: 
  • Net interest income was $63.7 million and net interest margin was 3.29%, with each better than the guidance range provided in the second quarter.
  • Net interest income was $63.7 million for the third quarter of 2023, compared to $63.0 million for the second quarter of 2023.
  • Provision for credit losses totaled $2.0 million for the third quarter of 2023 compared to $3.9 million in the second quarter of 2023.
  • Additionally, deposits excluding Brokered CDs increased by $172.8 million, while Brokered CDs decreased $76.6 million.

Amalgamated Financial Corp. Declares Regular Quarterly Dividend

Retrieved on: 
Tuesday, October 24, 2023
First Franklin Financial Corp., AMAL, Holding company

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced that its Board of Directors has declared a regular dividend to common stockholders of $0.10 per share, payable by the Company on November 24, 2023, to stockholders of record on November 7, 2023.

Key Points: 
  • NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced that its Board of Directors has declared a regular dividend to common stockholders of $0.10 per share, payable by the Company on November 24, 2023, to stockholders of record on November 7, 2023.
  • The amount and timing of any future dividend payments to stockholders will be subject to the discretion of the Board of Directors.

Amalgamated Financial Corp. Announces Third Quarter 2023 Earnings Conference Call

Retrieved on: 
Thursday, October 12, 2023
First Franklin Financial Corp., AMAL, Cryptocurrency

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced that its third quarter 2023 financial results will be released before market open on Thursday, October 26, 2023.

Key Points: 
  • NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (“Amalgamated” or the “Company”) (Nasdaq: AMAL) today announced that its third quarter 2023 financial results will be released before market open on Thursday, October 26, 2023.
  • The Company will host a conference call at 11:00 a.m. Eastern Time on the same day to discuss the financial results.
  • A live audio webcast of the conference call will be available on the website at https://ir.amalgamatedbank.com/ .
  • The replay will be available until November 2, 2023.

Mestag Therapeutics announces the appointment of expert advisors Dr. Cassandra Choe-Juliak, Dr. Greg Elson and Samantha Vieira MBA

Retrieved on: 
Thursday, October 12, 2023
Bachelor of Science, Ipsen, Bispecific monoclonal antibody, Affimer, MBA, Receptor (biochemistry), Acquisition, Doctor of Philosophy, MS, Development, Henley Business School, Breast, PMP, Multiple myeloma, University, AMAL, VCU Medical Center, Boehringer, Glenmark Pharmaceuticals, Biosimilar, Therapy, Georgetown University, Medical college, Merck, University of the Witwatersrand, Nightstar, Publication, Biogen, Lung, Selinexor, EMBA, Boehringer Ingelheim, XPO, Patient, Pharmaceutical industry, Molecular Immunology, Physiology, MD

"Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.

Key Points: 
  • "Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.
  • Cassandra Choe-Juliak, MD, MS, has spent more than 17 years in oncology medical affairs and clinical drug development.
  • Greg Elson, PhD, is co-founder and managing partner at Prevail Biopharma Solutions, and Chief Technology Officer at Alentis Therapeutics.
  • Samantha holds an EMBA from Henley Business School and BSc (Honours) in Physiology from University of the Witwatersrand, South Africa.

Amalgamated Financial Corp. Reports Second Quarter 2023 Financial Results; Immediate Liquidity Coverage at 183% of Uninsured Non Super-Core Deposits

Retrieved on: 
Thursday, July 27, 2023
Lender option borrower option, Insurance, SIVB, Risk-weighted asset, Amalgamated Bank, Share repurchase, Eastern Time Zone, Silicon Valley Bank, Trust, Common equity, FDIC, GAAP, Sale, AMAL, PACE, PACS, First Franklin Financial Corp., Earnings call, NOW, Total, Security (finance), Uranium mining, Bank, Video game, Pharmaceutical industry, Car rental, Rare-earth element, Amalgamation

Excluding uninsured super-core deposits of approximately $2.5 billion, remaining uninsured deposits were approximately 20-23% of total deposits with immediate liquidity coverage of 183%.

Key Points: 
  • Excluding uninsured super-core deposits of approximately $2.5 billion, remaining uninsured deposits were approximately 20-23% of total deposits with immediate liquidity coverage of 183%.
  • Net interest income was $63.0 million for the second quarter of 2023, compared to $67.3 million for the first quarter of 2023.
  • Our effective tax rate for the second quarter of 2023 was 26.5%, compared to 26.2% for the first quarter of 2023.
  • As previously announced, Amalgamated Financial Corp. will host a conference call to discuss its second quarter 2023 results today, July 27, 2023 at 11:00am (Eastern Time).